Diabetes Clinical Trial
Official title:
Evaluation of Group Lifestyle Balance Maintenance Strategies
Heart disease is a leading cause of death in people in the United States. It is a major
problem for those with diabetes. Conditions called the metabolic syndrome and pre-diabetes
increase risk for diabetes and heart disease. The metabolic syndrome is a group of disorders
that occur at the same time. Overall, one in four American adults has the metabolic
syndrome. It is more common in people over the age of 40. The metabolic syndrome includes:
1) large waist size, 2) high triglycerides, 3) low HDL cholesterol, 4) high blood pressure
and 5) high fasting blood sugar. People with the metabolic syndrome have at least three of
these five risk factors. Pre-diabetes is considered to be present in those with high fasting
blood sugar levels below the diabetes range.
Research has shown that type 2 diabetes and the metabolic syndrome may be prevented or
delayed by making lifestyle changes. It is not known what will most help people continue
these healthy changes over time. The purpose of this study is to look at ways to help people
continue the healthy lifestyle changes they have made while taking part in a diabetes
prevention program called Group Lifestyle Balance (GLB).
Objective: To determine the effectiveness of the Group Lifestyle Balance (GLB) program with
an added maintenance component focusing on carbohydrate reduction and hunger management when
compared to the GLB program with traditional maintenance.
Research Design and Methods: The original Diabetes Prevention Program intervention was
modified from a 16 session individual intervention to a 12 session group-based program
called Group Lifestyle Balance (GLB). The Diabetes Prevention Support Center (DPSC) has been
created to oversee the implementation of diabetes prevention and CVD risk reduction in
various community settings. GLB is a 12-session group based program that focuses on a low
fat diet, weight loss and physical activity. This evidence-based intervention is directed at
those with pre-diabetes and/or the metabolic syndrome. A monthly maintenance component will
be added which provides support in assisting individuals who have completed the 12-session
course in the maintenance of healthy lifestyle changes.
The efficacy (in terms of weight reduction) of an added maintenance component focusing on
carbohydrate reduction and hunger management will be compared to traditional maintenance.
Participants will be randomly assigned to either GLB traditional maintenance (GLB-TM) or GLB
and carbohydrate reduced maintenance (GLB-CRM). There will be two groups of approximately 15
subjects in each intervention assignment, for a total of approximately 30 subjects per
intervention group and approximately 60 subjects taking part overall. Efficacy in both
groups will be assessed by pre and post-intervention measures of diet (weight loss) and
physical activity (the keystones of the intervention), as well as the achievement of the two
goals: a 7% weight loss by the end of 6 months and 150 minutes of physical activity per
week. Secondary outcomes to be evaluated include the reduction of global CVD risk, as
assessed by the Framingham Score, the presence of metabolic syndrome (NCEP ATP III), and a
fall in blood sugar. Repeat measures will be obtained at six months and one year for further
evaluation and comparison.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05594446 -
Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
|
||
| Completed |
NCT03975309 -
DHS MIND Metabolomics
|
||
| Completed |
NCT01855399 -
Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes
|
N/A | |
| Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
| Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
| Recruiting |
NCT05007990 -
Caregiving Networks Across Disease Context and the Life Course
|
||
| Active, not recruiting |
NCT04420936 -
Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program
|
N/A | |
| Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
| Completed |
NCT04903496 -
Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
|
||
| Completed |
NCT01437592 -
Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
| Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
| Completed |
NCT03390179 -
Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
|
||
| Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
| Recruiting |
NCT05294822 -
Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes
|
N/A | |
| Completed |
NCT04427982 -
Dance and Diabetes/Prediabetes Self-Management
|
N/A | |
| Completed |
NCT02356848 -
STEP UP to Avert Amputation in Diabetes
|
N/A | |
| Completed |
NCT03292185 -
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
|
Phase 1 | |
| Active, not recruiting |
NCT05477368 -
Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes
|
N/A | |
| Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 |